Abstract:BACKGROUND: Persons with diabetes are at high risk of developing diabetic kidney disease (DKD), which is associated with high morbidity and mortality. Current drug therapies for DKD, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are not entirely satisfactory. This study aimed to evaluate the additional benefit and safety of the Chinese herbal granule Tangshen Formula (TSF) in treating DKD.METHODS: The study was designed as a six-center randomized, double-blind, placebo-controlled trial. From April 2007 through December 2009, 180 patients with DKD were enrolled. In addition to conventional treatment with ACEIs or ARBs, 122 participants were randomly assigned to receive TSF and 58 participants to receive placebo for 24 weeks. Primary outcome was urinary protein level, measured by urinary albumin excretion rate (UAER) for participants with microalbuminuria, 24-hour urinary protein (24h UP) for participants with macroalbuminuria. Secondary outcomes included renal function, serum lipids, quality of life, symptoms, and adverse events.FINDINGS: After 24 weeks of treatment, no statistically significant difference in UAER (TSF -19.53 μg/min compared with placebo -7.01 μg/min, with a mean difference of -12.52 μg/min; 95%CI, -68.67 to 43.63, P = 0.696) was found between TSF and placebo groups. However, TSF displayed a statistically significant decrease in 24h UP (TSF-0.21 g compared with placebo 0.36 g, with a mean difference of -0.57g; 95%CI, -1.05 to -0.09, P = 0.024). Estimated glomerular filtration rate (eGFR) was improved in both patients with microalbuminuria and macroalbuminuria, with a mean difference of 15.51 ml/min/1.73 m2 (95%CI, 3.71 to 27.31), 9.01 ml/min/1.73 m2 (95%CI, -0.10 to 18.13), respectively. Other secondary outcomes showed no statistically significant difference between groups or in the incidence of adverse events.CONCLUSIONS: Based on conventional treatments, TSF appears to provide additional benefits compared with placebo in decreasing proteinuria and improving eGFR in DKD patients with macroalbuminuria. Nevertheless, further study is needed to evaluate TSF treating patients with microalbuminuria.TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-TRC-10000843.

Effect of Tangshen Formula on the Purine and Pyrimidine Metabolism of Patients with Diabetic Nephropathy

[Effects of tangshen recipe on the homocysteine metabolism of patients with diabetic nephropathy].

Effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients

Effect of Tangshen Formula on Susceptibility Allele Expression of Hemodynamics in Patients with Diabetic Nephropathy

Effect of Qidi Xiaoke Prescription on C-peptide, Tumor Necrosis Factor-α, Interleukin-6, and Histopathological Changes of the Spleen in Rats with Type 2 Diabetes with Deficiency of Both Qi and Yin

Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial

Evidence for the involvement of JAK/STAT/SOCS pathway in the mechanism of Tangshen formula-treated diabetic nephropathy.

A Network Pharmacology-Based Approach for Exploring Key Active Compounds and Pharmacological Mechanisms of Tangshen Formula for Treatment of Diabetic Nephropathy

[A Metabonomic Study on the Treatment of Diabetic Nephropathy with Traditional Chinese Medicine Tang-Shen-fang].

Clinical Research of Tang Shen Ning in Treating Early Stage of Diabetic Nephropathy with Types of Deficiency of both Vital Energy and Yin and Collaterals Siltation and Stagnant

Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in db/db Mice Using Cytokine Antibody Array.

Metabolomic and lipidomic study of the protective effect of Chaihuang-Yishen formula on rats with diabetic nephropathy

Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats

Integrated chemical characterization, metabolite profiling, and pharmacokinetics analysis of Zhijun Tangshen Decoction by UPLC-Q/TOF-MS

Experimental Study of Xiezhuo Yishen Formula on Hyperuricemic Nephropathy

Suppression of ferroptosis through the SLC7A11/glutathione/glutathione peroxidase 4 axis contributes to the therapeutic action of the Tangshenning formula on diabetic renal tubular injury

Multicenter randomized and double-blind controlled clinical trial of Tang Shen Ning Granules in treating diabetic kidney disease

Clinical Study on the Recipe for Supplementing Qi,Nourishing Yin and Activating Blood Circulation for Treatment of 30 Cases of Diabetic Nephropathy

Effects of total flavones of Abelmoschus manihot (L.) on the treatment of diabetic nephropathy via the activation of solute carriers in renal tubular epithelial cells

Tangshen Decoction Enhances Podocytes Autophagy to Relieve Diabetic Nephropathy through Modulation of p-AMPK/p-ULK1 Signaling

Effect of Tianqi Capsule on metabolism of purines and pyrimidines in patients with impaired glucose tolerance